Regeneron Pharmaceuticals (REGN) Return on Capital Employed (2010 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Return on Capital Employed of 10.74% for Q2 2026, down 48.0% year-over-year from 20.66% in Q2 2025, and up 5.41% quarter-over-quarter from 10.19% in Q1 2026.
Regeneron Pharmaceuticals (REGN) Return on Capital Employed (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 10.74% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 48.0% year-over-year to 10.74%; the TTM figure through Jun 2026 stood at 10.74% (down 48.0% YoY), while the FY2025 annual figure was 10.28%, down 239.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 10.74%, up from 10.19% in the prior quarter.
- The five-year high for Return on Capital Employed was 39.73% in Q1 2022, with the low at 9.94% in Q4 2025.
- The 5-year median for Return on Capital Employed is 12.54% (2024), against an average of 15.96%.
- Peak annual rise in Return on Capital Employed reached 1174 bps in 2022, while the deepest fall reached 2466 bps in 2022.
- Regeneron Pharmaceuticals' Return on Capital Employed stood at 18.73% in 2022, then fell by 26 bps to 13.86% in 2023, then slipped by 14 bps to 11.86% in 2024, then slipped by 16 bps to 9.94% in 2025, then rose by 8 bps to 10.74% in 2026.
- Business Quant data shows REGN's Return on Capital Employed at 10.74% in Q2 2026, 10.19% in Q1 2026, and 9.94% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.74% |
| Mar 31, 2026 | 10.19% |
| Dec 31, 2025 | 9.94% |
| Sep 30, 2025 | 10.61% |
| Jun 30, 2025 | 11.23% |
| Mar 31, 2025 | 11.24% |
| Dec 31, 2024 | 11.86% |
| Sep 30, 2024 | 12.00% |
| Jun 30, 2024 | 12.31% |
| Mar 31, 2024 | 12.78% |
| Dec 31, 2023 | 13.86% |
| Sep 30, 2023 | 15.18% |
| Jun 30, 2023 | 15.90% |
| Mar 31, 2023 | 16.68% |
| Dec 31, 2022 | 18.73% |
| Sep 30, 2022 | 25.37% |
| Jun 30, 2022 | 28.87% |
| Mar 31, 2022 | 39.73% |
| Dec 31, 2021 | 43.39% |
| Sep 30, 2021 | 39.62% |